Real-World data sought on new myeloma combo
NCT ID NCT07532473
First seen Apr 20, 2026 · Last updated Apr 25, 2026 · Updated 2 times
Summary
This study will look back at medical records of 300 newly diagnosed multiple myeloma patients in the UK who cannot have a stem cell transplant and were treated with a combination of daratumumab, lenalidomide, and dexamethasone (DRd). The goal is to see how well this therapy works in everyday practice, including response rates and side effects. The study will not give any new treatments but will collect information to better understand real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Royal Wolverhampton NHS Trust
Wolverhampton, WV10 0QP, United Kingdom
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.